{
    "nct_id": "NCT04452357",
    "official_title": "RT-155: Utilizing Pulsed Low-dose-rate (PLDR) Radiation to Prevent de Novo Stromal Activation; a Neoadjuvant Pancreatic Adenocarcinoma Phase I Trial",
    "inclusion_criteria": "* Patients must have histologically or cytologically-confirmed pancreatic adenocarcinoma.\n* Patients must have non-metastatic pancreatic cancer not appropriate for immediate surgical resection. This includes the following:\n\n  * Any involvement (defined as loss of fat plane on contrast CT) of any of the following vessels*:\n\n    * Common hepatic artery\n    * Superior mesenteric artery\n    * Celiac axis\n    * Superior mesenteric vein\n    * Portal vein\n    * Aorta\n\n      * These criteria will be judged by the operating surgeon in conjunction with a radiologist prior to enrollment.\n  * Poor performance status not immediately conducive to radical surgery\n  * Other clinical reasoning by the treating physicians that supports pre-operative chemoradiation\n* Patients must have evaluable disease as measured by RECIST 1.1 criteria.\n* Planned surgical resection at the time of enrollment (may be initially staged as resectable, borderline resectable, or locally-advanced/unresectable).\n* Eastern Cooperative Oncology Group, or ECOG, performance status 0-2.\n* Adequate bone marrow, hepatic, renal function.\n\n  * ANC ³ 1,500/ml and PLT ³ 100,000/ml\n  * Bilirubin less than 1.5 ULN\n  * AST and ALT < 3X ULN\n  * Serum Creatinine <1.5X ULN\n* Prior chemotherapy allowed, but not mandatory. Patients who have undergone chemotherapy prior to participating in this study must have had a 2 week washout period at the time of signing the consent form.\n* Women of childbearing potential must be non-pregnant (negative pregnancy test within 72 hours prior to registration. Postmenopausal woman must have been amenorrheic and nonlactating for at least 12 months to be considered of non-childbearing potential. Men and women of child bearing potential must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for 3 months after therapy is completed. Please refer to section 6.4 for additional detail.\n* Age > 18 years\n* Participants must sign a written informed consent and HIPAA consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Radiological or cytologically confirmed metastatic disease\n* Patients who have had any prior therapy for pancreatic cancer, except chemotherapy (see 6.1.7)\n* Concurrent non-study chemotherapy or biologic therapy\n* A history of ataxia telangiectasia or other documented history of radiation hypersensitivity\n* Scleroderma or active connective tissue disease\n* Active inflammatory bowel disease\n* Serious, active infections requiring treatment with IV antibiotics\n* Uncontrolled intercurrent illness including, but not limited to, psychiatric illness/social situations that would limit compliance with study requirements.",
    "miscellaneous_criteria": ""
}